19 results on '"Daviaud, Isabelle"'
Search Results
2. Does seasonal vaccination affect the clinical presentation of influenza among the elderly? A cross-sectional analysis in the outpatient setting in France, 2003–2014
- Author
-
Mosnier, Anne, Daviaud, Isabelle, Caini, Saverio, Berche, Hervé, Mansuy, Jean-Michel, van der Werf, Sylvie, Cohen, Jean Marie, and Lina, Bruno
- Published
- 2017
- Full Text
- View/download PDF
3. Field seasonal influenza vaccine effectiveness: Evaluation of the screening method using different sources of data during the 2010/2011 French influenza season
- Author
-
Falchi, Alessandra, Souty, Cecile, Grisoni, Marie-Lise, Mosnier, Anne, Hanslik, Thomas, Daviaud, Isabelle, Varesi, Laurent, Kerneis, Solen, Carrat, Fabrice, and Blanchon, Thierry
- Published
- 2013
- Full Text
- View/download PDF
4. Systematic random versus ad hoc non random sampling strategy: does it modify estimations of influenza vaccine efficiency?
- Author
-
Cohen, Jean Marie, Mosnier, Anne, Daviaud, Isabelle, BUI, Tan Tai, Grog, Isidore, Valette, Martine, Enouf, Vincent, Lina, Bruno, and van der Werf, Sylvie
- Published
- 2011
5. Fib-4 score for assessment of liver fibrosis is useful in general practice
- Author
-
Denis Ouzan, Mosnier Anne, Guillaume Penaranda, Daviaud Isabelle, Françoise Barat, Joly Helene, Monelle Muntlak, and Cohen Jean Marie
- Subjects
Hepatology - Published
- 2020
6. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I‐MOVE multicentre test‐negative case‐control study, 2011/2012‐2016/2017
- Author
-
Valenciano, Marta, Kissling, Esther, Larrauri, Amparo, Nunes, Baltazar, Pitigoi, Daniela, O'Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabelle, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, de Lange, Marit, Kurečić Filipovićović, Sanja, Johansen, Kari, and Moren, Alain
- Subjects
vaccine effectiveness ,case-control study ,virus diseases ,ddc:610 ,influenza vaccine ,influenza ,610 Medizin und Gesundheit ,multicentre study - Abstract
Background Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent. Objectives To explore previous influenza vaccination effects on current season VE among population targeted for vaccination. Methods We used 2011/2012 to 2016/2017 I‐MOVE primary care multicentre test‐negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only. Results We included 941, 2645 and 959 influenza‐like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were −68%, −21% and −19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%). Conclusions We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects.
- Published
- 2018
7. Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009-2014
- Author
-
Casalegno, Jean-Sebastien, primary, Eibach, Daniel, additional, Valette, Martine, additional, Enouf, Vincent, additional, Daviaud, Isabelle, additional, Behillil, Sylvie, additional, Vabret, Astrid, additional, Soulary, Jean Claude, additional, Benchaib, Mehdi, additional, Cohen, Jean Marie, additional, van der Werf, Sylvie, additional, Mosnier, Anne, additional, and Lina, Bruno, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013
- Author
-
Blanchon, Thierry, Geffrier, Félicité, Turbelin, Clément, Daviaud, Isabelle, Laouénan, Cédric, Duval, Xavier, Lambert, Bruno, Hanslik, Thomas, Mosnier, Anne, Leport, Catherine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Biostatistiques, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC Hôpital Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service d'Etudes de Marché, International Metal Service of Health (IMS Health), Service de Médecine Interne, Hôpital Ambroise Paré [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Unité de Coordination des Risques Epidémiques et Biologiques, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
primary healthcare ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,treatment outcome ,epidemiologic factors ,Influenza ,neuraminidase inhibitors - Abstract
International audience; BACKGROUND:In a context of controversy about influenza antiviral treatments, this study assessed primary health-care physicians' prescription of neuraminidase inhibitors (NIs) in France during pandemic and seasonal influenza between 2009 and 2013.METHODS:This observational study, using data recorded in three national databases, estimated the rate of NI prescription among influenza-like illness (ILI) patients seen in GP and paediatrician consultations, and determined factors associated with this prescription according to a multivariate analysis. NI delivery by pharmacists was also evaluated.RESULTS:Rates of NI prescription were estimated to be 61.1% among ILI patients with a severe influenza risk factor seen in GP consultation during the A(H1N1)pdm2009 pandemic versus an average rate of 25.9% during the three following seasonal influenza epidemics. Factors associated with NI prescription were a chronic disease in patients under 65 years (OR 14.85; 95% CI 13.00, 16.97) and in those aged 65 and older (OR 7.54; 5.86, 9.70), an age ≥65 years in patients without chronic disease (OR 1.35; 1.04, 1.74), a pregnancy (OR 10.63; 7.67, 15.76), obesity (OR 4.67; 3.50, 6.22) and a consultation during the pandemic A(H1N1)pdm2009 (OR 3.19; 2.93, 3.48). The number of antiviral treatments delivered by pharmacists during the A(H1N1)pdm2009 pandemic was 835 per 100,000 inhabitants, and an average of 275 per 100,000 inhabitants during the three following seasonal influenza epidemics.CONCLUSIONS:Although physicians seem to follow the recommended indications for NIs in primary health-care practice, this study confirms the low rate of NI prescription to ILI patients with a severe influenza risk factor, especially during seasonal epidemics.
- Published
- 2015
9. Additional file 2: Table S1. of Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003–2013
- Author
-
Mosnier, Anne, Caini, Saverio, Daviaud, Isabelle, Jean-Louis Bensoussan, Stoll-Keller, Françoise, Bui, Tan, Lina, Bruno, Werf, Sylvie Van Der, and Cohen, Jean
- Subjects
virus diseases - Abstract
Weekly average (and median) of the estimated incidence (per 100,000 inhabitants) of medically-attended influenza. Data were only shown for virus type and subtypes that accounted for at least 1 % of all influenza cases in that season. Source: GROG influenza sentinel surveillance network, France, 2003–2004 to 2012–2013. (DOC 31 kb)
- Published
- 2015
- Full Text
- View/download PDF
10. Additional file 1: of Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003â 2013
- Author
-
Mosnier, Anne, Caini, Saverio, Daviaud, Isabelle, Jean-Louis Bensoussan, FrançOise Stoll-Keller, Bui, Tan, Lina, Bruno, Werf, Sylvie Van Der, and Cohen, Jean
- Abstract
GROG network. ARI and influenza incidence estimation. (DOC 92Â kb)
- Published
- 2015
- Full Text
- View/download PDF
11. IBGP : Étude Européenne du fardeau de la grippe B en médecine ambulatoire
- Author
-
Silva, Maria-Laura, Fleming, Douglas, Mosnier, Anne, Daviaud, Isabelle, Bui, Tan Taï, Paget, John, Cohen, Jean Marie, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, Netherlands Institute for Health Services Research, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), and Dao, Taï
- Subjects
Europe ,Surveillance ,General Practice ,Influenza B ,[SHS.ECO] Humanities and Social Sciences/Economics and Finance ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Published
- 2012
12. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe
- Author
-
Kissling, Esther, primary, Valenciano, Marta, additional, Cohen, Jean Marie, additional, Oroszi, Beatrix, additional, Barret, Anne-Sophie, additional, Rizzo, Caterina, additional, Stefanoff, Pawel, additional, Nunes, Baltazar, additional, Pitigoi, Daniela, additional, Larrauri, Amparo, additional, Daviaud, Isabelle, additional, Horvath, Judit Krisztina, additional, O'Donnell, Joan, additional, Seyler, Thomas, additional, Paradowska-Stankiewicz, Iwona Anna, additional, Pechirra, Pedro, additional, Ivanciuc, Alina Elena, additional, Jiménez-Jorge, Silvia, additional, Savulescu, Camelia, additional, Ciancio, Bruno Christian, additional, and Moren, Alain, additional
- Published
- 2011
- Full Text
- View/download PDF
13. Striking Similarities in the Presentation and Duration of Illness of Influenza A and B in the Community: A Study Based on Sentinel Surveillance Networks in France and Turkey, 2010-2012.
- Author
-
Cohen, Jean Marie, Silva, Maria Laura, Caini, Saverio, Ciblak, Meral, Mosnier, Anne, Daviaud, Isabelle, Matias, Gonçalo, Badur, Selim, Valette, Martine, Enouf, Vincent, Paget, John, Fleming, Douglas M., and null, null
- Subjects
INFLUENZA ,DISEASE duration ,GENERAL practitioners ,SOCIAL status - Abstract
Influenza B represents a high proportion of influenza cases in some seasons (even over 50%). The Influenza B study in General Practice (IBGP) is a multicenter study providing information about the clinical, demographic and socio-economic characteristics of patients affected by lab-confirmed influenza A or B. Influenza B patients and age-matched influenza A patients were recruited within the sentinel surveillance networks of France and Turkey in 2010–11 and 2011–12 seasons. Data were collected for each patient at the swab test day, after 9±2 days and, if not recovered, after 28±5 days. It was related to patient's characteristics, symptoms at presentation, vaccination status, prescriptions of antibiotics and antivirals, duration of illness, follow-up consultations in general practice or emergency room. We performed descriptive analyses and developed a multiple regression model to investigate the effect of patients and disease characteristics on the duration of illness. Overall, 774 influenza cases were included in the study: 419 influenza B cases (209 in France and 210 in Turkey) and 355 influenza A cases (205 in France and 150 in Turkey). There were no differences between influenza A and B patients in terms of clinical presentation and number of consultations with a practitioner; however, the use of antivirals was higher among influenza B patients in both countries. The average (median) reported duration of illness in the age groups 0–14 years, 15–64 years and 65+ years was 7.4 (6), 8.7 (8) and 10.5 (9) days in France, and 6.3 (6), 8.2 (7) and 9.2 (6) days in Turkey; it increased with age but did not differ by virus type; increased duration of illness was associated with antibiotics prescription. In conclusion, our findings show that influenza B infection appears not to be milder disease than influenza A infection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Clinical Characteristics Are Similar across Type A and B Influenza Virus Infections.
- Author
-
Mosnier, Anne, Caini, Saverio, Daviaud, Isabelle, Nauleau, Elodie, Bui, Tan Tai, Debost, Emmanuel, Bedouret, Bernard, Agius, Gérard, van der Werf, Sylvie, Lina, Bruno, Cohen, Jean Marie, and null, null
- Subjects
INFLUENZA viruses ,VIRUS diseases ,MEDICAL practice ,SYMPTOMS ,MEDICAL databases ,PATIENTS - Abstract
Background: Studies that aimed at comparing the clinical presentation of influenza patients across virus types and subtypes/lineages found divergent results, but this was never investigated using data collected over several years in a countrywide, primary care practitioners-based influenza surveillance system. Methods: The IBVD (Influenza B in Vircases Database) study collected information on signs and symptoms at disease onset from laboratory-confirmed influenza patients of any age who consulted a sentinel practitioner in France. We compared the clinical presentation of influenza patients across age groups (0–4, 5–14, 15–64 and 65+ years), virus types (A, B) and subtypes/lineages (A(H3N2), pandemic A(H1N1), B Victoria, B Yamagata). Results: Overall, 14,423 influenza cases (23.9% of which were influenza B) were included between 2003–2004 and 2012–2013. Influenza A and B accounted for over 50% of total influenza cases during eight and two seasons, respectively. There were minor differences in the distribution of signs and symptoms across influenza virus types and subtypes/lineages. Compared to patients aged 0–4 years, those aged 5–14 years were more likely to have been infected with type B viruses (OR 2.15, 95% CI 1.87–2.47) while those aged 15–64 years were less likely (OR 0.83, 95% CI 0.73–0.96). Males and influenza patients diagnosed during the epidemic period were less likely to be infected with type B viruses. Conclusions: Despite differences in age distribution, the clinical illness produced by the different influenza virus types and subtypes is indistinguishable among patients that consult a general practitioner for acute respiratory infections. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013.
- Author
-
Mosnier, Anne, Caini, Saverio, Daviaud, Isabelle, Bensoussan, Jean-Louis, Stoll-Keller, Françoise, Tan Tai Bui, Lina, Bruno, Van der Werf, Sylvie, and Cohen, Jean Marie
- Subjects
INFLUENZA A virus ,INFLUENZAVIRUS B ,INFLUENZA vaccines ,NASOPHARYNGITIS ,PUBLIC health - Abstract
Background: Describing the circulation of influenza viruses and the characteristics of seasonal epidemics remains an essential tool to optimize the strategies of influenza prevention and control. Special attention has been recently paid to influenza B in the context of the availability of a quadrivalent vaccine, containing two influenza B strains. Methods: We used data from a practitioners-based influenza surveillance network to describe the circulation of influenza viruses in France from 2003-2004 to 2012-2013. Nasopharyngeal swabs taken from acute respiratory infection (ARI) patients between October and April were tested for influenza. We reported the number of influenza cases by virus type (A, B), subtype (A(H1), A(H3)) and B lineage (Yamagata, Victoria) in each season and determined the frequency of influenza B vaccine mismatch. We estimated weekly incidence of influenza by extrapolating reported influenza cases to the French population. We compared the temporal characteristics of the epidemics caused by influenza A(H1), A(H3) and B. Results: Overall, 49,919 ARI patients were tested, of which 16,287 (32.6 %) were positive for influenza. Type B virus caused 23.7 % of all influenza cases. Virus subtypes A(H1) and A(H3) caused 51.6 % and 48.4 % of influenza A cases, respectively. Viruses of the B-Yamagata and B-Victoria lineage caused 62.8 % and 37.2 % of influenza B cases, respectively. There was an influenza B vaccine mismatch in three of the five seasons where influenza B caused 10 % or more of all influenza cases. Influenza A(H3) had the highest average value of estimated weekly incidence during the study period. Influenza B peaked an average 3.8 weeks later than influenza A when both virus types were circulating. No differences in the duration of influenza A and B epidemics were observed. Conclusions: Influenza A(H3) was the most prevalent influenza type during the study period. Influenza B caused around one fourth of all influenza cases and tended to circulate later than influenza A. The frequency of influenza B vaccine mismatches was substantial. Timely data on the circulation of influenza viruses collected within influenza surveillance systems are essential to optimize influenza prevention and control strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Does seasonal vaccination affect the clinical presentation of influenza among the elderly? A cross-sectional analysis in the outpatient setting in France, 2003–2014.
- Author
-
Caini, Saverio, Mosnier, Anne, Daviaud, Isabelle, Cohen, Jean Marie, Berche, Hervé, Mansuy, Jean-Michel, van der Werf, Sylvie, and Lina, Bruno
- Subjects
- *
FLU vaccine efficacy , *DISEASES in older people , *PUBLIC health surveillance , *ADULT respiratory distress syndrome , *OUTPATIENT medical care , *MEDICAL care , *VACCINATION - Abstract
Vaccine-induced protection against influenza is not optimal, however it has been suggested that the vaccine may reduce the severity of symptoms among those who develop illness despite being vaccinated. We tested this hypothesis within a countrywide, sentinel general practitioners-based surveillance system in France. We included 2277 individuals aged 65 years or older (of whom 1293 had been vaccinated against influenza, 56.8%) who consulted a general practitioner because of an acute respiratory infection (ARI) during 2003–2014. All patients were taken a nasopharyngeal swab, and information was collected on demographic characteristics and symptoms at disease onset. All specimens were tested for respiratory viruses and, if positive for influenza, the virus type and subtype were determined. We compared the average maximum temperature and the frequency of each symptom, between non-vaccinated and vaccinated influenza patients. We then used logistic regression models to calculate the odds of presenting with each symptom between vaccinated vs. non-vaccinated patients, adjusting by age group, virus (sub)type and season. Overall, 675 ARI patients (29.6%) tested positive for influenza. The A(H3) virus caused the majority of cases (55.1%), followed by influenza B (22.9%), A not-subtyped (11.7%), and A(H1) (10.3%) viruses. Compared to non-vaccinated influenza patients, those who had been vaccinated had a slightly reduced maximum temperature and presented less frequently with myalgia, shivering and headache. In stratified analyses, the observed effect was limited to patients infected with A(H3) or type B viruses. After adjusting by age group, virus (sub)type and season, the difference remained statistically significant only for headache, which was less frequent among vaccinated individuals (odds ratio 0.69, 95% confidence intervals 0.48–0.98). In conclusion, the vaccine was found to be modestly associated with less severe clinical presentation of influenza among the elderly. Our findings reinforce the need for influenza vaccines providing better protection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017.
- Author
-
Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O'Donnell J, Reuss A, Horváth JK, Paradowska-Stankiewicz I, Rizzo C, Falchi A, Daviaud I, Brytting M, Meijer A, Kaic B, Gherasim A, Machado A, Ivanciuc A, Domegan L, Schweiger B, Ferenczi A, Korczyńska M, Bella A, Vilcu AM, Mosnier A, Zakikhany K, de Lange M, Kurečić Filipovićović S, Johansen K, and Moren A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Influenza Vaccines administration & dosage, Influenza Vaccines immunology, Influenza, Human prevention & control
- Abstract
Background: Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent., Objectives: To explore previous influenza vaccination effects on current season VE among population targeted for vaccination., Methods: We used 2011/2012 to 2016/2017 I-MOVE primary care multicentre test-negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only., Results: We included 941, 2645 and 959 influenza-like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were -68%, -21% and -19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%)., Conclusions: We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects., (© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
18. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
- Author
-
Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, Cohen JM, Oroszi B, Rizzo C, Machado A, Pitigoi D, Domegan L, Paradowska-Stankiewicz I, Buchholz U, Gherasim A, Daviaud I, Horváth JK, Bella A, Lupulescu E, O Donnell J, Korczyńska M, and Moren A
- Subjects
- Case-Control Studies, Disease Outbreaks prevention & control, Europe epidemiology, Female, Humans, Influenza, Human virology, Male, Prevalence, Risk Factors, Treatment Outcome, Disease Outbreaks statistics & numerical data, Influenza Vaccines therapeutic use, Influenza, Human epidemiology, Influenza, Human prevention & control, Seasons, Vaccination statistics & numerical data
- Abstract
Since the 2008/9 influenza season, the I-MOVE multicentre case-control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0-65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1-15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9-67.9) and remained between this value and 50.3% (95% CI: 34.8-62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3-82.4) 44 days after vaccination to 21.4% (95% CI: -57.4-60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
- Published
- 2016
- Full Text
- View/download PDF
19. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
- Author
-
Blanchon T, Geffrier F, Turbelin C, Daviaud I, Laouénan C, Duval X, Lambert B, Hanslik T, Mosnier A, and Leport C
- Subjects
- Adolescent, Adult, Child, Comorbidity, Databases, Factual, Drug Prescriptions, Female, France epidemiology, Humans, Influenza A Virus, H1N1 Subtype drug effects, Male, Pandemics, Population Surveillance, Practice Patterns, Physicians', Risk Factors, Seasons, Young Adult, Antiviral Agents therapeutic use, Enzyme Inhibitors therapeutic use, Influenza, Human drug therapy, Influenza, Human epidemiology, Neuraminidase antagonists & inhibitors, Primary Health Care, Viral Proteins antagonists & inhibitors
- Abstract
Background: In a context of controversy about influenza antiviral treatments, this study assessed primary health-care physicians' prescription of neuraminidase inhibitors (NIs) in France during pandemic and seasonal influenza between 2009 and 2013., Methods: This observational study, using data recorded in three national databases, estimated the rate of NI prescription among influenza-like illness (ILI) patients seen in GP and paediatrician consultations, and determined factors associated with this prescription according to a multivariate analysis. NI delivery by pharmacists was also evaluated., Results: Rates of NI prescription were estimated to be 61.1% among ILI patients with a severe influenza risk factor seen in GP consultation during the A(H1N1)pdm2009 pandemic versus an average rate of 25.9% during the three following seasonal influenza epidemics. Factors associated with NI prescription were a chronic disease in patients under 65 years (OR 14.85; 95% CI 13.00, 16.97) and in those aged 65 and older (OR 7.54; 5.86, 9.70), an age ≥65 years in patients without chronic disease (OR 1.35; 1.04, 1.74), a pregnancy (OR 10.63; 7.67, 15.76), obesity (OR 4.67; 3.50, 6.22) and a consultation during the pandemic A(H1N1)pdm2009 (OR 3.19; 2.93, 3.48). The number of antiviral treatments delivered by pharmacists during the A(H1N1)pdm2009 pandemic was 835 per 100,000 inhabitants, and an average of 275 per 100,000 inhabitants during the three following seasonal influenza epidemics., Conclusions: Although physicians seem to follow the recommended indications for NIs in primary health-care practice, this study confirms the low rate of NI prescription to ILI patients with a severe influenza risk factor, especially during seasonal epidemics.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.